Circle Pharma announced on Wednesday, September 16, 2026 an oversubscribed $92.5 million Series E financing led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly and Company. The South San Francisco company said the money will take CID-165, which it describes as a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, through early clinical development in ER-positive breast cancer and support its broader pipeline of cyclin-targeted macrocycles. Circle expects CID-165 to enter clinical development in the first quarter of 2027.
Solstice Oncology, a Boston-based clinical-stage immuno-oncology company founded February 2026, announced Wednesday September 9, 2026 its formal launch and closing of an oversubscribed $225 million Series A financing to advance porustobart, a second-generation Fc-enhanced CTLA-4 monoclonal antibody licensed from Harbour BioMed. The Series A was led by RA Capital Management with participation from Canaan Partners, Forbion, and other investors. Porustobart is heading into a Phase 2 neoadjuvant trial combining with pembrolizumab (Merck's Keytruda) for microsatellite-stable clinical stage II-III colon cancer, targeting enrollment opening Q4 2026, plus a second undisclosed indication. Fc-enhancement is designed to improve the antibody's ability to deplete regulatory T-cells and enhance immunogenicity relative to first-generation CTLA-4 inhibitors like ipilimumab (Bristol Myers Squibb's Yervoy). The financing continues a Q3 2026 immuno-oncology financing wave and demonstrates continued investor appetite for differentiated checkpoint programs despite the maturity of the anti-PD-(L)1 class.
Typewriter Therapeutics announced Thursday September 3, 2026 its emergence from stealth with $56 million in Series A financing co-led by RA Capital Management and AN Venture Partners, with participation from ANRI, Gemseki, and SBI US Gateway Fund. The proceeds will advance the company's target-primed reverse transcription (TPRT) non-viral gene therapy platform toward clinical development, with initial focus on two high-value indications: in-vivo CAR-T and genetic liver diseases. TPRT uses jumping-gene-inspired biology to insert therapeutic DNA at specific target sites without the packaging-size constraints of AAV vectors or the payload delivery constraints of lipid nanoparticles. Typewriter plans to initiate non-human primate studies in late 2026 and establish its first in-vivo CAR-T development candidate over the next 12 months. The financing continues the H2 2026 in-vivo CAR-T financing wave that also delivered Umoja Biopharma's $100 million+ round and Capstan Therapeutics' Series C earlier in the summer.